Akebia Therapeutics (STU:AX9) ROCE %: -8.48% (As of Mar. 2026)

What is Akebia Therapeutics ROCE %?

Akebia Therapeutics STU:AX9 +8.59% 51 ROCE % is -8.48% as of Mar. 2026. GuruFocus rates STU:AX9 with a GF Score™ of 51/100 and a GF Value™ of €1.12 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Akebia Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -8.48%.

Akebia Therapeutics (STU:AX9) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Akebia Therapeutics ROCE % Related Terms

Akebia Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics ROCE % Chart

Akebia Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-76.36

-32.86

-24.47

-37.13

11.06

Akebia Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															30.57	12.30	10.23	-11.55	-8.48

51GF Score

Akebia Therapeutics Inc STU:AX9

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Akebia Therapeutics ROCE % Calculation

Akebia Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	17.471	/	( ( (210.74 - 77.273)	+	(321.587 - 139.149) )	/ 2 )
	=	17.471	/	( (133.467	+	182.438)	/ 2 )
	=	17.471	/	157.9525
	=	11.06 %

Akebia Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-14.66	/	( ( (321.587 - 139.149)	+	(313.58 - 150.41) )	/ 2 )
	=	-14.66	/	( ( 182.438	+	163.17 )	/ 2 )
	=	-14.66	/	172.804
	=	-8.48 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -8.48% mean?

Akebia Therapeutics (STU:AX9) has a ROCE % of -8.48% as of Mar. 2026.

Is Akebia Therapeutics' ROCE % too high?

Akebia Therapeutics' current ROCE % is -8.48%. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Akebia Therapeutics' ROCE % compare to TKNO and ORGO?

Akebia Therapeutics' ROCE % of -8.48% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current ROCE % is -8.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Akebia Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.12, compared to a current price of €0.98 — trading 12.6% below its estimated fair value. The current ROCE % is -8.48%. Akebia Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current ROCE % is -8.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €0.98 is trading 12.6% below its estimated GF Value™ of €1.12. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AX9:

ROCE %: -8.48%
GF Value™: €1.12 vs. price of €0.98 (12.6% below fair value)
GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TKNO ORGO SIGA ANIK LFCR ELTP DERM EBS ASRT NIKA XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges AKBA:USA

Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142

Website https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

51GF Score

Get the complete analysis for STU:AX9

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.98

Price

€1.12

GF Value

View STU:AX9 Analysis

See ROCE % data for all stocks →